Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease by Barrett, Jeffrey C. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genome-wide association defines more than 30 distinct
susceptibility loci for Crohn's disease
Citation for published version:
Barrett, JC, Hansoul, S, Nicolae, DL, Cho, JH, Duerr, RH, Rioux, JD, Brant, SR, Silverberg, MS, Taylor, KD,
Barmada, MM, Bitton, A, Dassopoulos, T, Datta, LW, Green, T, Griffiths, AM, Kistner, EO, Murtha, MT,
Regueiro, MD, Rotter, JI, Schumm, LP, Steinhart, AH, Targan, SR, Xavier, RJ, Libioulle, C, Sandor, C,
Lathrop, M, Belaiche, J, Dewit, O, Gut, I, Heath, S, Laukens, D, Mni, M, Rutgeerts, P, Van Gossum, A,
Zelenika, D, Franchimont, D, Hugot, J-P, de Vos, M, Vermeire, S, Louis, E, Cardon, LR, Anderson, CA,
Drummond, H, Nimmo, E, Ahmad, T, Prescott, NJ, Onnie, CM, Fisher, SA, Marchini, J, Ghori, J,
Bumpstead, S, Gwilliam, R, Tremelling, M, Deloukas, P, Mansfield, J, Jewell, D, Satsangi, J, Mathew, CG,
Parkes, M, Georges, M, Daly, MJ & NIDDK IBD Genetics Consortium, Belgian-French IBD Consortium,
Wellcome Trust Case Control 2008, 'Genome-wide association defines more than 30 distinct susceptibility
loci for Crohn's disease' Nature Genetics, vol 40, no. 8, pp. 955-962. DOI: 10.1038/ng.175
Digital Object Identifier (DOI):
10.1038/ng.175
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Nature Genetics
Publisher Rights Statement:
Published in final edited form as:
Nat Genet. 2008 August ; 40(8): 955–962. doi:10.1038/NG.175.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Genome-wide association defines more than thirty distinct
susceptibility loci for Crohn's disease
Jeffrey C. Barrett1, Sarah Hansoul2, Dan L. Nicolae3, Judy H. Cho4, Richard H. Duerr5,6,
John D. Rioux7,8, Steven R. Brant9,10, Mark S. Silverberg11, Kent D. Taylor12, M. Michael
Barmada5, Alain Bitton13, Themistocles Dassopoulos9, Lisa Wu Datta9, Todd Green8, Anne
M. Griffiths14, Emily O. Kistner15, Michael T. Murtha4, Miguel D. Regueiro6, Jerome I.
Rotter12, L. Philip Schumm15, A. Hillary Steinhart11, Stephan R. Targan12, Ramnik J.
Xavier16, the NIDDK IBD Genetics Consortium, Cécile Libioulle2, Cynthia Sandor2, Mark
Lathrop17, Jacques Belaiche18, Olivier Dewit19, Ivo Gut17, Simon Heath17, Debby
Laukens20, Myriam Mni2, Paul Rutgeerts21, André Van Gossum22, Diana Zelenika17, Denis
Franchimont22, JP Hugot23, Martine de Vos20, Severine Vermeire21, Edouard Louis18, the
Belgian-French IBD consortium, the Wellcome Trust Case Control Consortium, Lon R.
Cardon1, Carl A. Anderson1, Hazel Drummond24, Elaine Nimmo24, Tariq Ahmad25, Natalie
J Prescott26, Clive M. Onnie26, Sheila A. Fisher26, Jonathan Marchini27, Jilur Ghori28,
Suzannah Bumpstead28, Rhian Gwillam28, Mark Tremelling29, Panos Deloukas28, John
Mansfield30, Derek Jewell31, Jack Satsangi24, Christopher G. Mathew26, Miles Parkes29,
Michel Georges2, and Mark J. Daly8,32
1Bioinformatics and Statistical Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford,
Roosevelt Drive, Oxford OX3 7BN, UK
2Unit of Animal Genomics, GIGA-R & Faculty of Veterinary Medicine, University of Liège, Belgium
3University of Chicago, Department of Medicine, 5801 South Ellis, Chicago, Illinois 60637, USA
4Yale University, Departments of Medicine and Genetics, Division of Gastroenterology, Inflammatory Bowel
Disease (IBD) Center, 300 Cedar Street, New Haven, Connecticut 06519, USA
5University of Pittsburgh, Graduate School of Public Health, Department of Human Genetics, 130 Desoto
Street, Pittsburgh, Pennsylvania 15261, USA
6University of Pittsburgh, School of Medicine, Department of Medicine, Division of Gastroenterology,
Hepatology and Nutrition, University of Pittsburgh Medical Center (UPMC) Presbyterian, 200 Lothrop
Street, Pittsburgh, Pennsylvania 15213, USA
7Université de Montréal and the Montreal Heart Institute, Research Center, 5000 rue Belanger, Montreal,
Quebec H1T 1C8, Canada
8The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA
9Johns Hopkins University, Department of Medicine, Harvey M. and Lyn P. Meyerhoff Inflammatory Bowel
Disease Center, 1503 East Jefferson Street, Baltimore, Maryland 21231, USA
10Johns Hopkins University, Bloomberg School of Public Health, Department of Epidemiology, 615 E. Wolfe
Street, Baltimore, Maryland 21205, USA
11Mount Sinai Hospital IBD Centre, University of Toronto, 441-600 University Avenue, Toronto, Ontario
M5G 1X5, Canada
Article on Nature Genetics website: http://www.nature.com/ng/journal/vaop/ncurrent/abs/ng.175.html
NIH Public Access
Author Manuscript
Nat Genet. Author manuscript; available in PMC 2009 May 1.
Published in final edited form as:
Nat Genet. 2008 August ; 40(8): 955–962. doi:10.1038/NG.175.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
12Medical Genetics Institute and Inflammatory Bowel Disease (IBD) Center, Cedars-Sinai Medical Center,
8700 W. Beverly Blvd., Los Angeles, California 90048, USA
13Department of Medicine, Royal Victoria Hospital, McGill University, Montreal, Quebec, H3A 1A1, Canada
14The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8,
Canada
15University of Chicago, Department of Health Studies, 5841 S. Maryland Avenue, Chicago, Illinois 60637,
USA
16Gastrointestinal Unit and Center for Computational and Integrative Biology, Massachusetts General
Hospital, Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
17Centre National de Génotypage, Evry, France
18Unit of Hepatology and Gastroenterology, Department of Clinical Sciences, GIGA-R, Faculty of Medicine
and CHU de Liège, University of Liège, Belgium
19Department of gastroenterology, Clinique universitaire St Luc, UCL, Brussels, Belgium
20Department of Hepatology and Gastroenterology, Ghent University Hospital, Belgium
21Departrment of Gastroenterology, University Hospital Leuven, Belgium
22Department of Gastroenterology, Erasmus Hospital, Free University of Brussels, Belgium
23INSERM; Université Paris Diderot; Assistance Publique Hôpitaux de Paris; Hopital Robert Debré, Paris,
Fance
24Gastrointestinal Unit, Division of Medical Sciences, School of Molecular and Clinical Medicine, University
of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK
25Peninsula Medical School, Barrack Road, Exeter, EX2 5DW
26Department of Medical and Molecular Genetics, King's College London School of Medicine, 8th Floor
Guy's Tower, Guy's Hospital, London, SE1 9RT, UK
27Department of Statistics, University of Oxford, 1 South Parks Road, Oxford OX1 3TG, UK
28The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA,
UK
29IBD research group, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 2QQ, UK
30Department of Gastroenterology & Hepatology, University of Newcastle upon Tyne, Royal Victoria
Infirmary, Newcastle upon Tyne NE1 4LP, UK
31Gastroenterology Unit, Radcliffe Infirmary, University of Oxford, Oxford, OX2 6HE, UK
32Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, 185
Cambridge Street, Boston, Massachusetts 02114, USA
Abstract
Several new risk factors for Crohn's disease have been identified in recent genome-wide association
studies. To advance gene discovery further we have combined the data from three studies (a total of
3,230 cases and 4,829 controls) and performed replication in 3,664 independent cases with a mixture
of population-based and family-based controls. The results strongly confirm 11 previously reported
loci and provide genome-wide significant evidence for 21 new loci, including the regions containing
STAT3, JAK2, ICOSLG, CDKAL1, and ITLN1. The expanded molecular understanding of the basis
of disease offers promise for informed therapeutic development.
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The first genome-wide association studies (GWAS) have identified many common variants
associated with complex diseases, and have rapidly expanded our knowledge of the genetic
architecture of these traits. Progress in Crohn's disease (CD), a common idiopathic
inflammatory bowel disease (IBD) with high heritability (λs ∼ 20-35), has been especially
striking, with recent GWAS publications increasing the number of confirmed associated loci
from two to more than ten 1. The results have identified new pathogenic mechanisms of IBD
and promise to advance fundamentally our understanding of CD biology. These recent
discoveries highlight, for instance, the key importance of autophagy and innate immunity2-5
as determinants of the dysregulated host-bacterial interactions implicated in disease
pathogenesis. Furthermore, genetic associations have been shown to be shared between CD
and other auto-inflammatory conditions – for example, IL23R variants 6 are also associated
with psoriasis7 and ankylosing spondylitis8, and PTPN2 variants with type 1 diabetes3,5. As
in other complex diseases, restricted sample sizes have resulted in early CD studies focusing
on only the strongest effects, which turn out to explain only a fraction of the heritability of
disease.
We recently published three separate GWA scans for CD in European-derived populations –
the details of which are shown in Table 14,5,9. Motivated by the need for larger datasets to
improve power to detect loci of modest effect, we carried out a genome-wide meta-analysis
from our three CD scans. These analyses, together with a replication study in an equivalently
sized, independent panel, have enabled us to identify at genome-wide levels of significance 21
novel Crohn's disease susceptibility genes and loci. This brings the total number of independent
loci conclusively associated with Crohn's disease to more than 30 and provides unprecedented
insight into both CD pathogenesis as well as the general genetic architecture of a multifactorial
disease.
Results
Meta-analysis of three genome-wide association scans
The combined GWAS study samples (Table 1) consisted of 3,230 cases and 4,829 controls,
all of European descent. While the individual scans did identify new risk factors, they were
only well-powered to discover common alleles with odds-ratios (ORs) above 1.3 (in the case
of the WTCCC) or 1.5 (the smaller two scans, Figure 1). By contrast, the combined sample
has 74% power at an OR of 1.2, allowing evaluation of the role of alleles with smaller effect
sizes for the first time. As two different genotyping technologies were used in the constituent
scans, we utilized recently developed imputation10,11 methods to assess association across all
three studies at 635,547 SNPs contained on one or both platforms. A quantile-quantile (Q-Q)
plot of the primary meta-statistic (single SNP Z-scores, Figure 2) shows a striking excess of
significant associations, well beyond what would be attributable to the modest overall
distributional inflation (genomic control λ < 1.16). Despite the large sample size, the overall
inflation is modest because (1) each group had separately tested for evidence of population
stratification, and the meta-analysis used a test that combined the results from each study (rather
than mixing the raw data and compromising the case-control matching of each study), and (2)
imputation was done on all samples ignoring case status and thus would not introduce
artifactual differences between cases and controls12.
We focus our attention in this study specifically on the 526 SNPs from 74 distinct genomic
loci which were associated with p < 5×10-5 – more than 7 times the number of SNPs expected
by chance even after correction for the modest overall inflation detected. This threshold for
follow-up is not meant to imply that there are no genuine associations among SNPs with less
significant association in the meta-analysis, but rather reflects a practical desire to prioritize
as many true positives as possible for immediate replication. Eleven associations previously
replicated and established at genome-wide significance levels (Methods, Table 2), including
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both “historical” associations at NOD213,14 and 5q31 (IBD5) 15 as well as recent replicated
findings from individual GWA scans such as IL23R, ATG16L1, IRGM, TNFSF15 and
PTPN22-6,16, were among the 74 regions represented in this tail of the distribution of
association statistics. Even after removing all SNPs in LD with these eleven loci, however,
there continued to be a substantial excess of associated alleles beyond that which would be
expected by chance (Figure 2).
Replication of 21 new loci
As these 74 regions included the 11 already reported as independently replicated and meeting
genome-wide significance thresholds, this replication experiment effectively explored 63
putative associations in novel regions with 11 positive controls (Supplementary Table 1). To
identify the true risk factors from these 63 regions, we undertook a replication study involving
a total of 2,325 additional Crohn's disease cases and 1,809 controls alongside an independent
family-based dataset of 1,339 parent-parent-affected offspring trios.
Results (significance levels and odds ratios) for strongly replicating loci, including all positive
controls, are presented in Table 2. The distribution of Z-scores from the 63 putative regions
shows a dramatic departure from the null distribution (Figure 3) with 19 novel regions showing
significant replication (p < 0.0008 – a value of 0.05/63 representing a conservative threshold
expected to be exceeded only once by chance in 20 such replication experiments). SNPs on
chromosome 19p13 (replication p = 0.00347, combined p = 2.12×10-9) and in the MHC
(replication p = 0.006, combined p = 5.2×10-9 - suspected but not previously conclusively
established in Crohn's disease) did not reach this conservative threshold, but so convincingly
satisfy proposed thresholds for genome-wide significance (p<5×10-8, Methods) that we
propose these as the 20th and 21st additional Crohn's disease associated loci defined here. A
further 8 of the 42 remaining loci showed nominal replication (Table 3).
It is possible that extreme population substructure in the replication sample could give rise to
such a striking excess of hits. While unlikely, this was directly evaluated by the large family-
based component of the replication study. Odds ratio estimates from the TDT analysis of the
North American, French and Belgian families alone are consistent with those from the UK and
Belgian case/control samples (Tables 2 & 3), with all 21 newly defined loci showing odds
ratios in the same direction of association with the original scan in the family-based component
(and nearly half showing greater OR than in the case-control arm). Importantly, none of the
significantly or nominally replicating loci show significant evidence for heterogeneity (across
studies or between family-based and population-based arms) when corrected for the number
of tests performed. This independent family based evidence (Supplementary Table 6) confirms
these alleles constitute true Crohn's disease loci.
For this newly expanded set of 32 unequivocally associated loci, we assessed whether there
was evidence of significant pairwise interactions which could add further to the overall variance
in liability explained by this set of loci. We performed a case-only analysis of the 3,664 cases
in the replication study and observed no interactions that withstood a correction for the number
of tests performed (Supplementary Table 2).
Deciphering the genetic architecture of CD
The contributions of the 32 loci to disease risk were computed using a standard liability
threshold model and are displayed as a histogram of individual variances (Figure 4). The
observations from this variance analysis that many loci were detected for which the current
study had low power, and that only a minority of the variance in risk is explained by these 32
loci, suggest that many additional loci are yet to be identified. This is reinforced by the
additional 8 nominal replications (Table 3) where only 2 or 3 would be expected by chance,
Barrett et al. Page 4
Nat Genet. Author manuscript; available in PMC 2009 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and by the continued excess of small p values when these 40 total regions are removed (Figure
2).
While recognizing that fine-mapping is required to identify specific causal variants, we
performed a series of analyses to gain some general insight into the CD associations. We first
queried HapMap to discover any instances where a non-synonymous SNP (nsSNP) was
correlated (r2 > 0.5) to the most associated variant discovered in this study. Accepting that
HapMap is not a complete catalogue of nsSNPs, but including four loci where fine-mapping
has identified coding variants, just 9 of the 32 genomewide significant associations were
correlated with a known nsSNP (Supplementary Table 3). To explore whether any of the
associations reflect a cis-acting regulatory effect on a nearby gene, we evaluated genotype-
expression correlation using the panel of 400 lymphoblastoid cell lines described by Dixon et
al.17. From all genes within 250 kb of the LD-based intervals defined in Table 2 and 3, five
correlations between expression of a nearby gene and a CD-associated variant were identified
(LOD > 2) (Supplementary Table 4). This was far in excess of chance (p∼0.001)
(Supplementary Figure 1) and suggests that regulatory variation also contributes to the genetic
architecture identified.
Discussion
Genome-wide association studies provide a systematic assessment of the contribution of
common variation to disease pathogenesis. A limiting factor is often the size of the case-control
dataset, and hence the power to detect any but the most strongly associated loci. Meta-analysis
of existing data provides an obvious potential solution. As Figure 1 demonstrates, our
expectation was that the additional power of the combined dataset would result in the
identification of a substantially larger number of readily replicating associations than were
derived from any of the smaller, constituent datasets. However, the paradigm of exploring
common genetic variation with similar effects across studies (in this case all of European
descent) needs testing before its results can be accepted as valid.
On the validity of the method our results are substantially reassuring. All 11 previously
confirmed CD susceptibility loci were strongly replicated both in the meta-analysis and follow-
up experiment. These include the two widely replicated findings from studies published in
200113-15 as well as all of the compelling findings from individual GWAS (Table 2 a).
Significantly, we have also identified and replicated 21 new CD susceptibility loci. Using a
conservative threshold for significance (only 1 such region would be expected by chance in 20
such experiments), the loci with clear evidence for association in the replication panel include
a very high proportion of those showing strongest signals in the meta-analysis (Supplementary
Table 1) – 9 of 9 previously unreported regions with p < 5×10-7 in the combined scan were
replicated convincingly - emphasizing the validity of the meta-analysis results. Further
emphasizing the robustness of these results, all 21 of these loci exceed a conservative genome-
wide level of significance (p < 5×10-8) by a significant margin (all but two have p < 5×10-9) -
and equivalent strength of association was observed in the family-based subset of our
replication sample.
In keeping with other regions recently identified as associated with CD, the 21 new loci do not
conform to any obvious pattern in terms of gene content. Thus, as shown in Table 2, some loci
(defined by HapMap recombination hotspots flanking the set of correlated, associated variants)
contain just a single gene, some contain many genes and others none. Clearly the first category
provides the most immediate clues regarding pathogenic mechanisms. These genes are
discussed briefly in Box 1, together with a number of genes which constitute striking candidates
from regions with only a handful of transcripts. Included among these are compelling functional
candidates such as STAT3, JAK2 and IL12B while others, such as CDKAL1 and PTPN22,
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highlight potentially intriguing contrasts between genetic susceptibility to Crohn's disease and
some other complex disorders (Box 1). It is noteworthy – and consistent with previous findings
from CD and other complex diseases – that we did not find any strong evidence of deviation
from the model of multiplicative (random) effects when we tested for gene-gene interactions
among the 32 confirmed associations. This is in spite of the fact that some of these genes seem
to affect the same or overlapping pathways.
For loci containing multiple genes or no genes the picture is less well defined. The identified
paucity of correlation between associated SNPs and coding variation suggests that these loci
may, in particular, benefit from eQTL (expression quantitative trait locus) analysis. This seeks
correlation between genotype and expression patterns – bearing in mind that such functional
relationships need not respect the specific boundaries of LD around the association. One of
our groups previously reported an eQTL effect incriminating PTGER4 at the 5p13 locus9. A
striking outcome from our present analysis was at the established IBD5 locus 15, where CD-
associated SNPs were associated with decreased SLC22A5 mRNA expression levels. While a
SNP had previously been proposed as regulating SLC22A5 transcriptional activity18, these
data suggest for the first time that the most disease-associated variants in the IBD5 region,
including a coding variant in neighboring SLC22A4, are the same variants most associated with
SLC22A5 expression. Equally striking, the most significant Crohn's disease associated eQTL
reported here affects ORMDL3 (LOD = 20) on chromosome 17 and SNPs in precisely the same
region were recently shown to be strongly associated with childhood asthma.19 This suggests
that the same polymorphisms might underlie susceptibility to both CD and asthma, possibly
by perturbing ORMDL3 expression.
The new loci that we have identified are of modest effect size, which is unsurprising given all
loci with larger impact on disease risk were – as might be expected – discovered in the original
scans. The small sizes of these effects explains the lack of overlap between linkage results in
CD and these newly discovered loci (Supplementary Figure 2), with the possible exceptions
of combined effects of multiple high ranking associations on chromosomes 5q and 6p. Indeed,
the linkage evidence that led to the discovery of the IBD5 locus was very likely boosted by the
nearby effects at IL12B and IRGM. As expected, the only gene conclusively discovered via
linkage (NOD2) is one of two loci which stand well out from the remainder of the distribution
of effect sizes (Figure 4). The other outlier, IL23R, illustrates an interesting characteristic of
linkage – because (unlike NOD2) the most penetrant risk allele has very high frequency (93%),
it is nearly invisible to linkage analysis despite the high OR; highly protective rare alleles are
simply not present in multiplex affected families and thus do not influence allele sharing
substantially.
Using a liability-threshold model, we estimate that the 32 loci identified to date explain about
10% of the overall variance in disease risk, which may be as much as a fifth of the genetic risk,
given previous estimates of CD heritability of approximately 50%.20 This observation is
consistent with the fact that these loci collectively contribute only a factor of two to sibling
relative risk (λs), and even this figure is dominated by the substantial contribution of NOD2
variants. However, it should be emphasized that the full impact of the new loci cannot be
determined until causal variants have been identified by directed sequencing and fine-mapping
experiments. Until then the proportion of the variance in Crohn's disease risk explained must
be measured from the confirmed SNPs, where association is due to LD with causal variants.
Since multiple causal variants might exist at each locus (ranging in frequency from rare to
common) our estimates of variance explained provide only a lower bound for the true
contribution of each locus.
In conjunction with results from a very similar gene discovery effort in type 2 diabetes21,
common lessons are beginning to emerge with respect to the genetic architecture of complex
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traits. In each example, substantial increase in sample size achieved through meta-analysis has
led to dramatic success in gene discovery. In all cases, this progress has revealed an underlying
architecture consistent with many individually modest effects which conventional genetic
linkage analysis, and even the largest individual genome-wide association studies, are not well
powered to detect. Common variants explaining more than 1% of the genetic variance are rare,
whereas well-powered studies have found dozens of variants contributing 0.1% of overall
variance in liability. Perhaps surprisingly, neither we nor others have yet to document a
substantial role for epistasis among these loci and a number of associated loci are conclusively
mapped to regions with no currently annotated protein coding genes. Despite the considerable
concordant success, a distinct minority of the overall heritability has been explained by these
documented associations.
Since our study is well-powered to identify loci that explain > 0.2% of the overall variance,
but the sum of such loci explains a relatively small fraction of the total, it seems likely that
many loci with even more modest effect sizes remain undiscovered. Of particular note is the
continued excess of associations outside of the regions studied here, as well as the nominal
replication of an additional 8 loci, notably greater than expected by chance. Overall, the
distribution of Z scores in the replication experiment is clearly skewed towards replication –
only 11 of the 63 Z-scores in this replication experiment generate Z<0. If only the 21 strongly
confirmed loci were genuinely associated, half of the 42 remaining should end up with Z<0.
Indeed, observing 8 of the 42 remaining tests with Z>1.5 is itself a highly significant
observation (p < 0.0001). Although modest in terms of effect size, identification of such loci
is likely to still provide important insights into pathogenic mechanisms, as biological
importance need not be proportional to the statistical evidence for genetic association. Closer
inspection of regions showing nominal association in the replication experiment reveals that a
number of transcripts in these loci are of considerable interest, including CCL2/CCL722,
IL18RAP23 and GCKR24.
It is important to note that the generation of GWAS arrays used in the scans here did not offer
complete genome coverage of common variation (additional loci may reside in poorly covered
intervals) and did not address either rare SNPs or copy number variation effectively. Thus in
spite of the wealth of new susceptibility genes and loci identified by the current study, it seems
implausible that there are not more to be found – albeit very large datasets are likely to be
required to achieve robust statistical support for them. With respect to the present findings,
there is much work to be done in resequencing and fine mapping to identify causal variants.
While we do not yet have a complete understanding of the genetic architecture of Crohn's
disease, dramatic progress has now been made towards this goal - and with it the prospect of
directed functional exploration of the pathways identified, insight into how risk alleles interact
with environmental modifiers, and the hope of new avenues for treatment.
BOX 1
Noteworthy genes within loci newly implicated in Crohn's pathogenesis
• Chemokine receptor 6 (CCR6): encoding a member of the G protein-coupled
chemokine receptor family, this homing receptor is expressed by immature
dendritic cells and memory T cells and is important for B-cell differentiation and
tissue specific migration of dendritic and T cells during epithelial inflammatory
and immunological responses 25. The ligand of this receptor is macrophage
inflammatory protein 3 alpha (MIP-3 alpha); both genes are expressed in
granulomas of pulmonary sarcoid 26. Recent studies have also demonstrated that
CCR6, IL23R and RORγT are selectively expressed by IL-17 producing cells and
IFNγ producing TH17/TH1 cells in CD27.
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• Interleukin IL12B: encodes the p40 subunit which is a constituent of both
heterodimeric interleukins IL-12 and IL-2328. Association with CD was
previously reported5 but not confirmed, and it is also known to be associated with
psoriasis7. The key role of the IL12/IL23 pathway in chronic intestinal
inflammation is supported by the association between IL23R and CD3 and strong
functional evidence from mouse models of colitis 29-32.
• Signal transducer and activator of transcription 3 (STAT3) and Janus kinase 2
(JAK2): the JAK-STAT pathway is a focal point in signal transmission
downstream of cytokine and growth factor signals from cell surface receptors to
the nucleus to modify transcription of various genes, notably in hematopoietic
cells. The present findings are particularly significant, given the role of both genes
in IL23R signaling 33, and the central role STAT3 in Th17 differentiation 34.
However, JAK2 or STAT3 are also downstream of several other cytokines
implicated in CD pathogenesis in addition to interleukin 23, highlighting the
pathophysiologic complexity of these new associations. Further complexity is
highlighted by the distinctly different roles of STAT3 in innate versus adaptive
immunity in murine colitis models: activation of STAT3 in innate immune cells
enhances mucosal barrier function whereas STAT3 activation in T-cells
exacerbates colitis.
• Leucine-rich repeat kinase 2 (LRRK2). This gene encodes a multi-domain protein
expressed mainly in the cytoplasm of neurons, myeloid cells and monocytes, and
mutations in LRRK2 have been strongly associated with Parkinson's disease35. A
recent study reported the induction of autophagy by mutant LRRK2,41 which is of
interest given the strong associations between CD and the autophagy genes
ATG16L1 and IRGM.2-5 The same locus also contains the gene MUC19, which
encodes a large protein with multiple serine/threonine-rich repeats characteristic
of the mucin gene family. The mucin proteins are core components of the mucus
layer which protects the intestinal epithelia from injury, and mucin-deficiency
potentiates intestinal inflammation in mouse models of colitis36.
• CDKAL1: the protein encoded by this gene is poorly characterized, but
CDKAL1 is noteworthy for being recently confirmed as a type 2 diabetes
susceptibility gene 24,37-39. In this study, we find that SNPs from the same intron
of CDKAL1 that shows association with T2D are associated with CD, but the
associated alleles for the two diseases are not correlated with each other.
• Inducible T-cell co-stimulator ligand (ICOSLG): this co-stimulatory molecule is
expressed on intestinal (and other) epithelial cells and may play a role in their
antigen presentation to and regulation of mucosal T lymphocytes40. Upon
maturation, plasmacytoid dendritic cells express ICOSLG and drive the generation
of IL-10 producing T regulatory cells41.
• Protein tyrosine phosphatase, non-receptor types 2 and 22 (PTPN2 and
PTPN22). Both of these genes are associated with other autoimmune and
inflammatory diseases and the effect described here for PTPN2 is similar to that
previously described for type 1 diabetes (T1D) 42. However, the association of
PTPN22 with CD, although mapping to the same coding variant (R602W) that is
a risk factor for T1D and rheumatoid arthritis,43,44 is in the opposite direction,
with the T1D and RA risk allele, 602W, offering protection from CD.
• Intelectin 1 (ITLN1) is known to be expressed in human small bowel and colon,
and encodes a 120-kDa homotrimeric lectin recognizing galactofuranosyl residues
found in cell walls of various microorganisms but not in mammals45. Human
intelectin-1 is structurally identical to the lactoferrin receptor (LFR), expressed
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within the enterocyte brush border, and appears critical in membrane stabilization,
preventing loss of digestive enzymes, and protecting the glycolipid microdomains
from pathogens46. In addition, intelectin expression is reported in Paneth cells in
both mouse and pig small intestine, further pointing to a role in innate immunity.
Methods
Crohn's disease patients, controls, and GWAS
The meta-analysis was based on data from the 3 genome-wide scans of the NIDDK4,
WTCCC5 and Belgian/French9 studies. Details of the numbers of cases and controls genotyped
in the respective scans and of the genotyping platforms used are shown in Table 1, as are case/
control and family cohorts genotyped in the replication study of the meta-analysis. Details of
the ascertainment and characterization of these cohorts, as well as quality control procedures
applied to the GWA datasets, were provided in the original scan and replication publications
3, 4, 5, 6, 9. Recruitment of study subjects was approved by local and national institutional
review boards, and informed consent was obtained from all participants.
Imputation
Briefly, these methods rely on observed haplotype patterns in a set of reference data (the
HapMap) and the actual genotype data from each project to make predictions (along with a
measure of statistical certainty) at un-genotyped SNPs. We used the program MACH 10 with
the NIDDK and Belgian/French data, and IMPUTE 11 with the WTCCC data. Comparisons
between the two algorithms yielded very similar results (data not shown). We imputed the
superset of polymorphic markers which passed QC in the original scans4,5,9. This set was
comprised of SNPs on either the Affymetrix 500K only (n = 350,507), Illumina HumanHap300
version 1 only (n = 238,935), or both panels (n = 46,105) such that all association tests
performed were at least partially based on observed genotype data.
Test for association, effect size estimation and interactions
Using the genotype probabilities (rather than best-guess genotypes) and empirical variances
for imputed markers in the case and control tallies, we summarized the standard 1 d.f. allele-
based test of association as a Z-score within each scan and combined scores across studies to
produce a single meta-statistic for each SNP across all three datasets. Odds ratios were
estimated separately in TDT samples and each case/control replication collection, and then
combined and tested for heterogeneity. 47 Interaction tests were performed using the case-only
epistasis test implemented in PLINK48.
Critical regions
Given that most associations contain many correlated SNPs showing signal, we demarcated
independent loci by first defining the set of HapMap SNPs with r2 > 0.5 to the most significantly
associated SNP. We then bounded the “critical region” by the flanking HapMap recombination
hotspots which contained this set. These windows very likely contain the causal
polymorphisms explaining the associations.
Replication
We defined loci to have been previously confirmed if an earlier study had both detected and
replicated the association in independent samples and the association achieved p < 5 × 10-8
(recently proposed as an appropriate genome-wide significance level for GWAS49). For
replication genotyping, we selected the most significantly associated SNP from each region
along with a second, correlated SNP with p<0.0001 or a second assay on the opposite strand
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in order to have a technical backup should the first fail genotyping (Supplementary Table 1).
Replication genotyping for the putatively associated loci was performed using primer extension
chemistry and mass spectrometric analysis (iPLEX, Sequenom) using Sequenom Genetics
Services (N. American panel) and Genome Research Limited, Wellcome Trust Sanger Institute
(UK panel), and using a custom-made Golden Gate assay on a Beadstation500 (Illumina),
following the manufacturer's recommendations (Belgian/French panel). The more completely
genotyped SNP of the two from each region was chosen to represent that regional association
in analysis (if both were completely typed, the SNP that was more strongly associated in the
scan was used). Samples with >10% missing data (n = 267 for Belgian/French data, 111 for
the UK data and 8 for the N. American data; these samples are not included in the tallies for
Table 1), as well as SNPs with >10% missing data or Hardy-Weinberg p value < 0.001 were
excluded from this analysis.
Regional Annotation: eQTL analysis
Effects of SNPs in Tables 2 & 3 on expression levels of neighbouring genes was studied using
transcriptome data from the ∼400 lymphoblastoid cell lines described by Dixon et al.17. SNPs
that were not genotyped on this panel (n=14) were replaced with a proxy with r2 > 0.95 when
possible (n=12). LOD scores > 2 for genes (probe average) located within 250 Kb of the
corresponding LD windows were retrieved from
http://www.sph.umich.edu/csg/liang/asthma/. To evaluate the significance of the findings with
the CD associated SNPs, we compared the observed (i) number of genes yielding LOD scores
> 2, and (ii) sum of these LOD scores, with the corresponding frequency distributions for 1,000
randomly selected sets of 31SNPs, matched for allele frequency (± 0.02) and gene context.
Window sizes determined for associated SNPs were used for the matched simulated SNPs.
URL
Meta-analysis test statistics and allele frequencies for all SNPs are available at:
http://www.broad.mit.edu/∼jcbarret/ibd-meta/
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Power to detect a genetic effect of various sizes (odds ratio 1.2, 1.3, 1.5) versus study sample
size. Power is reported here as the probability (given a multiplicative model and risk allele
frequency of 20%) of p < 5×10-5 in a scan – the value used to define regions for attempting
replication in a larger sample set. Vertical dotted lines show the sample sizes for the three
constituent scans and the meta-analysis. Relatively large effects are likely to be detected by
any of these scans, whereas only the combined analysis is well powered to detect more modest
effects.
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Figure 2.
A quantile-quantile plot of observed -log10 p values versus the expectation under the null.
Black points represent the complete meta-analysis, with a substantial departure from the null
at the tail (values > 8 are represented along the top of the plot as triangles). Dark blue points
show the distribution after removing 11 previously published loci, demonstrating a still notable
excess. Light blue points show the distribution after removing all 40 loci which replicate at
least nominally. In all the cases the overall distribution is marginally inflated (λGC < 1.16).
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Figure 3.
Distribution of observed Z scores from the 63 novel regions explored, along with the expected
distribution under the null (a standard normal with mean 0 and variance 1). Even setting aside
the 21 regions reaching genome-wide significance, the distribution is highly skewed – 4 more
results exceed a Z of 2 (1 would be expected by chance under the null) whilst none showed a
Z of less than -2 (same expectation under the null) suggesting that even more of the regions
investigated here are likely to constitute true positive associations when additional data become
available.
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Figure 4.
Histogram of percent variance explained by each of the 32 established CD risk loci. The
distribution resembles the long postulated exponential distribution of effect sizes. Dashed line
shows the joint power for our meta-analysis to detect (p < 5×10-5), and for our replication
sample to replicate (at Bonferroni corrected p values), a 20% variant explaining a given fraction
of variance. Note how quickly this curve moves from nearly zero power to detect tiny effects
(less than one tenth of one percent) to nearly full power to detect larger effects (presuming they
are well covered by the current generation of GWAS chips). Complete power near the origin
would likely reveal a more complete exponential distribution, with many very small effects.
These are likely to increase somewhat once the causal variant or variants are identified in each
locus. Indeed, NOD2 and IL23R are distant outliers, each explaining 1-2% of total variance,
partially because multiple causal variants have already been discovered at these loci6,13.
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Table 1
Samples used (post QC) in this study
NIDDK BEL/FR UKIBDGC Total
Scan cases 946 536 1,748 3,230
Scan controls 977 914 2,938 4,829
Replication cases 0 1,082 1,243 2,325
Replication controls 0 787 1,022 1,809
Replication Trios 720 619 0 1,339
Nationality USA/Canadian Belgian/French British
Scan Platform Illumina HumanHap300 Illumina HumanHap300 Affymetrix GeneChip 500K
Replication Platform Sequenom Illumina GoldenGate Sequenom
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